The FDA has issued a drug shortage report for Foradil Aerolizer formoterol fumarate inhalation powder due to discontinuation of the product.
According to the FDA website: “Novartis (manufacturer) and Merck have jointly decided to voluntarily discontinue manufacture of Foradil Aerolizer for business reasons. It is anticipated that inventory will be exhausted and no longer distributed in or around January 2016, though inventory may be exhausted earlier. Health care providers are encouraged to identify an appropriate alternative treatment as soon as possible.”
Foradil was approved by the FDA in February 2001 for the treatment of asthma and in September 2001 for the treatment of COPD.
View the FDA notice.
